Ozempic-Like Medications Show Potential to Alter Alcohol Cravings
Recent findings indicate that medications similar to Ozempic, particularly those containing semaglutide, may have an unexpected impact on alcohol cravings. Some individuals taking these drugs report a significant change in their desire for alcohol, leading researchers to explore their potential benefits for those with alcohol use disorder. A review published in Biological Psychiatry consolidates various studies that examine this phenomenon, highlighting both promising possibilities and critical distinctions in outcomes.
Semaglutide is part of a class of medications that mimic GLP-1, a hormone that plays a role in appetite regulation and blood sugar control. Researchers are now investigating whether these drugs can also modify individuals' relationships with alcohol. Mette Kruse Klausen and Anders Fink-Jensen, Danish researchers, analyzed randomized trials, health record studies, and personal accounts from individuals using these medications.
In one significant study, 127 participants seeking help for alcohol use disorder received psychotherapy in conjunction with either weekly injections of the GLP-1 drug exenatide or a placebo. The results indicated that exenatide did not lead to a significant reduction in heavy drinking days compared to the placebo group. However, an exploratory analysis suggested that participants with obesity may have experienced some benefits from the treatment. Brain scans from a subset of participants revealed a diminished response to alcohol-related imagery in areas of the brain associated with reward, although these findings do not definitively establish that the drug is effective solely for individuals with obesity or clarify the reasons behind changes in drinking behavior.
Another research effort involved testing semaglutide on 48 individuals with alcohol use disorder who were not actively seeking treatment. Those receiving the drug demonstrated a decrease in alcohol consumption during laboratory tests compared to the placebo group. Participants reported fewer drinks on days they consumed alcohol and experienced reduced weekly cravings. Nonetheless, the drug did not significantly alter the number of drinking days or the average amount consumed per day.
The distinction between craving, the amount consumed on drinking days, and the frequency of drinking is crucial. The most robust evidence comes from a 26-week trial published in The Lancet, which involved 108 individuals with obesity seeking treatment for moderate-to-severe alcohol use disorder. All participants received cognitive behavioral therapy alongside either semaglutide injections or a placebo. The results indicated that semaglutide led to a significant reduction in heavy drinking days, with a 41.1-percentage-point reduction from baseline compared to 26.4 points with placebo, marking a treatment difference of 13.7 percentage points. Participants receiving semaglutide also reduced their overall alcohol intake more than those on the placebo.
Fink-Jensen, a co-author of the study, emphasized that the evidence increasingly supports the notion that semaglutide can effectively reduce heavy drinking and overall consumption. However, the evidence regarding its effect on cravings is still inconsistent. A newer randomized trial of oral semaglutide found fewer heavy drinking days, but its primary measure of craving triggered by alcohol-related cues did not show significant differences from the placebo. A separate measure of cravings reported in daily life did show improvement, indicating a complex relationship between the medication and craving.
Health record studies have also suggested a correlation between GLP-1 prescriptions and a reduction in alcohol-related incidents. While these studies can track large populations, they cannot definitively prove causation regarding reduced alcohol consumption.
The underlying mechanisms through which a diabetes medication could influence alcohol consumption are still being explored. Factors such as the brain's reward response, appetite regulation, and slower gastric emptying may play roles. However, researchers have yet to determine which mechanisms are most significant.
Furthermore, it remains unclear who would benefit most from these medications. The largest trial involving semaglutide focused solely on individuals with obesity, while smaller studies have not established a clear relationship between treatment efficacy and body mass index. It is also uncertain whether any observed reductions in drinking are independent of weight loss.
Fink-Jensen noted that while obesity might affect responses to GLP-1 receptor agonists, the importance of BMI as a treatment modifier is still unknown. Side effects such as nausea and digestive issues are associated with these drugs, and further research is needed to identify who benefits, the long-term effects post-treatment, and how GLP-1 drugs compare to existing treatments for alcohol use disorder, such as naltrexone and acamprosate.
In conclusion, while semaglutide may help some individuals reduce heavy drinking, questions remain about its ability to diminish cravings and the specific populations that may benefit. The ongoing research into these medications represents a promising avenue for addressing alcohol use disorder, but more extensive and longer trials are necessary to clarify their effectiveness and mechanisms of action.




